The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Idiopathic Urticaria Treatment Market Research Report 2025
Synopsis
The global Chronic Idiopathic Urticaria Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chronic Idiopathic Urticaria Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Idiopathic Urticaria Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Chronic Idiopathic Urticaria Treatment include Merck, Pfizer, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi, Mylan N.V., Novartis AG, Allakos Inc. and Novan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Idiopathic Urticaria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Idiopathic Urticaria Treatment.
Report Scope
The Chronic Idiopathic Urticaria Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Idiopathic Urticaria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Idiopathic Urticaria Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Pfizer
Bayer AG
Teva Pharmaceutical Industries Ltd
Sanofi
Mylan N.V.
Novartis AG
Allakos Inc.
Novan
GlaxoSmithKline plc
Nuvo Pharmaceuticals
Eli Lilly and Company
AstraZeneca plc
AbbVie Inc.
Celldex Therapeutics
Segment by Type
Tablets
Capsules
Creams
Lotions
Injections
Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Idiopathic Urticaria Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Idiopathic Urticaria Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Chronic Idiopathic Urticaria Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chronic Idiopathic Urticaria Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Idiopathic Urticaria Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Chronic Idiopathic Urticaria Treatment include Merck, Pfizer, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi, Mylan N.V., Novartis AG, Allakos Inc. and Novan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Idiopathic Urticaria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Idiopathic Urticaria Treatment.
Report Scope
The Chronic Idiopathic Urticaria Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Idiopathic Urticaria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Idiopathic Urticaria Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Pfizer
Bayer AG
Teva Pharmaceutical Industries Ltd
Sanofi
Mylan N.V.
Novartis AG
Allakos Inc.
Novan
GlaxoSmithKline plc
Nuvo Pharmaceuticals
Eli Lilly and Company
AstraZeneca plc
AbbVie Inc.
Celldex Therapeutics
Segment by Type
Tablets
Capsules
Creams
Lotions
Injections
Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Idiopathic Urticaria Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Idiopathic Urticaria Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Chronic Idiopathic Urticaria Treatment Market Overview
1.1 Product Overview and Scope of Chronic Idiopathic Urticaria Treatment
1.2 Chronic Idiopathic Urticaria Treatment Segment by Type
1.2.1 Global Chronic Idiopathic Urticaria Treatment Market Value Comparison by Type (2024-2030)
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Creams
1.2.5 Lotions
1.2.6 Injections
1.3 Chronic Idiopathic Urticaria Treatment Segment by Application
1.3.1 Global Chronic Idiopathic Urticaria Treatment Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.3.4 Retail Pharmacies
1.4 Global Chronic Idiopathic Urticaria Treatment Market Size Estimates and Forecasts
1.4.1 Global Chronic Idiopathic Urticaria Treatment Revenue 2019-2030
1.4.2 Global Chronic Idiopathic Urticaria Treatment Sales 2019-2030
1.4.3 Global Chronic Idiopathic Urticaria Treatment Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Chronic Idiopathic Urticaria Treatment Market Competition by Manufacturers
2.1 Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Manufacturers (2019-2024)
2.2 Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Chronic Idiopathic Urticaria Treatment Average Price by Manufacturers (2019-2024)
2.4 Global Chronic Idiopathic Urticaria Treatment Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chronic Idiopathic Urticaria Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chronic Idiopathic Urticaria Treatment, Product Type & Application
2.7 Chronic Idiopathic Urticaria Treatment Market Competitive Situation and Trends
2.7.1 Chronic Idiopathic Urticaria Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Chronic Idiopathic Urticaria Treatment Players Market Share by Revenue
2.7.3 Global Chronic Idiopathic Urticaria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chronic Idiopathic Urticaria Treatment Retrospective Market Scenario by Region
3.1 Global Chronic Idiopathic Urticaria Treatment Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Chronic Idiopathic Urticaria Treatment Global Chronic Idiopathic Urticaria Treatment Sales by Region: 2019-2030
3.2.1 Global Chronic Idiopathic Urticaria Treatment Sales by Region: 2019-2024
3.2.2 Global Chronic Idiopathic Urticaria Treatment Sales by Region: 2025-2030
3.3 Global Chronic Idiopathic Urticaria Treatment Global Chronic Idiopathic Urticaria Treatment Revenue by Region: 2019-2030
3.3.1 Global Chronic Idiopathic Urticaria Treatment Revenue by Region: 2019-2024
3.3.2 Global Chronic Idiopathic Urticaria Treatment Revenue by Region: 2025-2030
3.4 North America Chronic Idiopathic Urticaria Treatment Market Facts & Figures by Country
3.4.1 North America Chronic Idiopathic Urticaria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2030)
3.4.3 North America Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Chronic Idiopathic Urticaria Treatment Market Facts & Figures by Country
3.5.1 Europe Chronic Idiopathic Urticaria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2030)
3.5.3 Europe Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Chronic Idiopathic Urticaria Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Chronic Idiopathic Urticaria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2030)
3.6.3 Asia Pacific Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Chronic Idiopathic Urticaria Treatment Market Facts & Figures by Country
3.7.1 Latin America Chronic Idiopathic Urticaria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2030)
3.7.3 Latin America Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Chronic Idiopathic Urticaria Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Chronic Idiopathic Urticaria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2030)
3.8.3 Middle East and Africa Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chronic Idiopathic Urticaria Treatment Sales by Type (2019-2030)
4.1.1 Global Chronic Idiopathic Urticaria Treatment Sales by Type (2019-2024)
4.1.2 Global Chronic Idiopathic Urticaria Treatment Sales by Type (2025-2030)
4.1.3 Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Type (2019-2030)
4.2 Global Chronic Idiopathic Urticaria Treatment Revenue by Type (2019-2030)
4.2.1 Global Chronic Idiopathic Urticaria Treatment Revenue by Type (2019-2024)
4.2.2 Global Chronic Idiopathic Urticaria Treatment Revenue by Type (2025-2030)
4.2.3 Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Chronic Idiopathic Urticaria Treatment Price by Type (2019-2030)
5 Segment by Application
5.1 Global Chronic Idiopathic Urticaria Treatment Sales by Application (2019-2030)
5.1.1 Global Chronic Idiopathic Urticaria Treatment Sales by Application (2019-2024)
5.1.2 Global Chronic Idiopathic Urticaria Treatment Sales by Application (2025-2030)
5.1.3 Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Application (2019-2030)
5.2 Global Chronic Idiopathic Urticaria Treatment Revenue by Application (2019-2030)
5.2.1 Global Chronic Idiopathic Urticaria Treatment Revenue by Application (2019-2024)
5.2.2 Global Chronic Idiopathic Urticaria Treatment Revenue by Application (2025-2030)
5.2.3 Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Chronic Idiopathic Urticaria Treatment Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Chronic Idiopathic Urticaria Treatment Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Chronic Idiopathic Urticaria Treatment Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Bayer AG
6.3.1 Bayer AG Corporation Information
6.3.2 Bayer AG Description and Business Overview
6.3.3 Bayer AG Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bayer AG Chronic Idiopathic Urticaria Treatment Product Portfolio
6.3.5 Bayer AG Recent Developments/Updates
6.4 Teva Pharmaceutical Industries Ltd
6.4.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.4.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.4.3 Teva Pharmaceutical Industries Ltd Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Pharmaceutical Industries Ltd Chronic Idiopathic Urticaria Treatment Product Portfolio
6.4.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi Chronic Idiopathic Urticaria Treatment Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Mylan N.V.
6.6.1 Mylan N.V. Corporation Information
6.6.2 Mylan N.V. Description and Business Overview
6.6.3 Mylan N.V. Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mylan N.V. Chronic Idiopathic Urticaria Treatment Product Portfolio
6.6.5 Mylan N.V. Recent Developments/Updates
6.7 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG Chronic Idiopathic Urticaria Treatment Product Portfolio
6.7.5 Novartis AG Recent Developments/Updates
6.8 Allakos Inc.
6.8.1 Allakos Inc. Corporation Information
6.8.2 Allakos Inc. Description and Business Overview
6.8.3 Allakos Inc. Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Allakos Inc. Chronic Idiopathic Urticaria Treatment Product Portfolio
6.8.5 Allakos Inc. Recent Developments/Updates
6.9 Novan
6.9.1 Novan Corporation Information
6.9.2 Novan Description and Business Overview
6.9.3 Novan Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novan Chronic Idiopathic Urticaria Treatment Product Portfolio
6.9.5 Novan Recent Developments/Updates
6.10 GlaxoSmithKline plc
6.10.1 GlaxoSmithKline plc Corporation Information
6.10.2 GlaxoSmithKline plc Description and Business Overview
6.10.3 GlaxoSmithKline plc Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GlaxoSmithKline plc Chronic Idiopathic Urticaria Treatment Product Portfolio
6.10.5 GlaxoSmithKline plc Recent Developments/Updates
6.11 Nuvo Pharmaceuticals
6.11.1 Nuvo Pharmaceuticals Corporation Information
6.11.2 Nuvo Pharmaceuticals Chronic Idiopathic Urticaria Treatment Description and Business Overview
6.11.3 Nuvo Pharmaceuticals Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Nuvo Pharmaceuticals Chronic Idiopathic Urticaria Treatment Product Portfolio
6.11.5 Nuvo Pharmaceuticals Recent Developments/Updates
6.12 Eli Lilly and Company
6.12.1 Eli Lilly and Company Corporation Information
6.12.2 Eli Lilly and Company Chronic Idiopathic Urticaria Treatment Description and Business Overview
6.12.3 Eli Lilly and Company Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Eli Lilly and Company Chronic Idiopathic Urticaria Treatment Product Portfolio
6.12.5 Eli Lilly and Company Recent Developments/Updates
6.13 AstraZeneca plc
6.13.1 AstraZeneca plc Corporation Information
6.13.2 AstraZeneca plc Chronic Idiopathic Urticaria Treatment Description and Business Overview
6.13.3 AstraZeneca plc Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.13.4 AstraZeneca plc Chronic Idiopathic Urticaria Treatment Product Portfolio
6.13.5 AstraZeneca plc Recent Developments/Updates
6.14 AbbVie Inc.
6.14.1 AbbVie Inc. Corporation Information
6.14.2 AbbVie Inc. Chronic Idiopathic Urticaria Treatment Description and Business Overview
6.14.3 AbbVie Inc. Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.14.4 AbbVie Inc. Chronic Idiopathic Urticaria Treatment Product Portfolio
6.14.5 AbbVie Inc. Recent Developments/Updates
6.15 Celldex Therapeutics
6.15.1 Celldex Therapeutics Corporation Information
6.15.2 Celldex Therapeutics Chronic Idiopathic Urticaria Treatment Description and Business Overview
6.15.3 Celldex Therapeutics Chronic Idiopathic Urticaria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Celldex Therapeutics Chronic Idiopathic Urticaria Treatment Product Portfolio
6.15.5 Celldex Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chronic Idiopathic Urticaria Treatment Industry Chain Analysis
7.2 Chronic Idiopathic Urticaria Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chronic Idiopathic Urticaria Treatment Production Mode & Process
7.4 Chronic Idiopathic Urticaria Treatment Sales and Marketing
7.4.1 Chronic Idiopathic Urticaria Treatment Sales Channels
7.4.2 Chronic Idiopathic Urticaria Treatment Distributors
7.5 Chronic Idiopathic Urticaria Treatment Customers
8 Chronic Idiopathic Urticaria Treatment Market Dynamics
8.1 Chronic Idiopathic Urticaria Treatment Industry Trends
8.2 Chronic Idiopathic Urticaria Treatment Market Drivers
8.3 Chronic Idiopathic Urticaria Treatment Market Challenges
8.4 Chronic Idiopathic Urticaria Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Chronic Idiopathic Urticaria Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Chronic Idiopathic Urticaria Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Chronic Idiopathic Urticaria Treatment Market Competitive Situation by Manufacturers in 2023
Table 4. Global Chronic Idiopathic Urticaria Treatment Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Chronic Idiopathic Urticaria Treatment Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Chronic Idiopathic Urticaria Treatment Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Chronic Idiopathic Urticaria Treatment Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Chronic Idiopathic Urticaria Treatment, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Chronic Idiopathic Urticaria Treatment, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Chronic Idiopathic Urticaria Treatment, Product Type & Application
Table 12. Global Key Manufacturers of Chronic Idiopathic Urticaria Treatment, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Chronic Idiopathic Urticaria Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Idiopathic Urticaria Treatment as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Chronic Idiopathic Urticaria Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Chronic Idiopathic Urticaria Treatment Sales by Region (2019-2024) & (K Units)
Table 18. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Region (2019-2024)
Table 19. Global Chronic Idiopathic Urticaria Treatment Sales by Region (2025-2030) & (K Units)
Table 20. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Region (2025-2030)
Table 21. Global Chronic Idiopathic Urticaria Treatment Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Region (2019-2024)
Table 23. Global Chronic Idiopathic Urticaria Treatment Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Region (2025-2030)
Table 25. North America Chronic Idiopathic Urticaria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2024) & (K Units)
Table 27. North America Chronic Idiopathic Urticaria Treatment Sales by Country (2025-2030) & (K Units)
Table 28. North America Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Chronic Idiopathic Urticaria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Chronic Idiopathic Urticaria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2024) & (K Units)
Table 32. Europe Chronic Idiopathic Urticaria Treatment Sales by Country (2025-2030) & (K Units)
Table 33. Europe Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Chronic Idiopathic Urticaria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Chronic Idiopathic Urticaria Treatment Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Chronic Idiopathic Urticaria Treatment Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Chronic Idiopathic Urticaria Treatment Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Chronic Idiopathic Urticaria Treatment Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Chronic Idiopathic Urticaria Treatment Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Chronic Idiopathic Urticaria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Chronic Idiopathic Urticaria Treatment Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Chronic Idiopathic Urticaria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Chronic Idiopathic Urticaria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Chronic Idiopathic Urticaria Treatment Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Chronic Idiopathic Urticaria Treatment Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Chronic Idiopathic Urticaria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Chronic Idiopathic Urticaria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Chronic Idiopathic Urticaria Treatment Sales (K Units) by Type (2019-2024)
Table 51. Global Chronic Idiopathic Urticaria Treatment Sales (K Units) by Type (2025-2030)
Table 52. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Type (2019-2024)
Table 53. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Type (2025-2030)
Table 54. Global Chronic Idiopathic Urticaria Treatment Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Chronic Idiopathic Urticaria Treatment Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Type (2019-2024)
Table 57. Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Type (2025-2030)
Table 58. Global Chronic Idiopathic Urticaria Treatment Price (US$/Unit) by Type (2019-2024)
Table 59. Global Chronic Idiopathic Urticaria Treatment Price (US$/Unit) by Type (2025-2030)
Table 60. Global Chronic Idiopathic Urticaria Treatment Sales (K Units) by Application (2019-2024)
Table 61. Global Chronic Idiopathic Urticaria Treatment Sales (K Units) by Application (2025-2030)
Table 62. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Application (2019-2024)
Table 63. Global Chronic Idiopathic Urticaria Treatment Sales Market Share by Application (2025-2030)
Table 64. Global Chronic Idiopathic Urticaria Treatment Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Chronic Idiopathic Urticaria Treatment Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Application (2019-2024)
Table 67. Global Chronic Idiopathic Urticaria Treatment Revenue Market Share by Application (2025-2030)
Table 68. Global Chronic Idiopathic Urticaria Treatment Price (US$/Unit) by Application (2019-2024)
Table 69. Global Chronic Idiopathic Urticaria Treatment Price (US$/Unit) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Merck Chronic Idiopathic Urticaria Treatment Product
Table 74. Merck Recent Developments/Updates
Table 75. Pfizer Corporation Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Pfizer Chronic Idiopathic Urticaria Treatment Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Bayer AG Corporation Information
Table 81. Bayer AG Description and Business Overview
Table 82. Bayer AG Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Bayer AG Chronic Idiopathic Urticaria Treatment Product
Table 84. Bayer AG Recent Developments/Updates
Table 85. Teva Pharmaceutical Industries Ltd Corporation Information
Table 86. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 87. Teva Pharmaceutical Industries Ltd Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Teva Pharmaceutical Industries Ltd Chronic Idiopathic Urticaria Treatment Product
Table 89. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Sanofi Chronic Idiopathic Urticaria Treatment Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Mylan N.V. Corporation Information
Table 96. Mylan N.V. Description and Business Overview
Table 97. Mylan N.V. Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Mylan N.V. Chronic Idiopathic Urticaria Treatment Product
Table 99. Mylan N.V. Recent Developments/Updates
Table 100. Novartis AG Corporation Information
Table 101. Novartis AG Description and Business Overview
Table 102. Novartis AG Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Novartis AG Chronic Idiopathic Urticaria Treatment Product
Table 104. Novartis AG Recent Developments/Updates
Table 105. Allakos Inc. Corporation Information
Table 106. Allakos Inc. Description and Business Overview
Table 107. Allakos Inc. Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Allakos Inc. Chronic Idiopathic Urticaria Treatment Product
Table 109. Allakos Inc. Recent Developments/Updates
Table 110. Novan Corporation Information
Table 111. Novan Description and Business Overview
Table 112. Novan Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Novan Chronic Idiopathic Urticaria Treatment Product
Table 114. Novan Recent Developments/Updates
Table 115. GlaxoSmithKline plc Corporation Information
Table 116. GlaxoSmithKline plc Description and Business Overview
Table 117. GlaxoSmithKline plc Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. GlaxoSmithKline plc Chronic Idiopathic Urticaria Treatment Product
Table 119. GlaxoSmithKline plc Recent Developments/Updates
Table 120. Nuvo Pharmaceuticals Corporation Information
Table 121. Nuvo Pharmaceuticals Description and Business Overview
Table 122. Nuvo Pharmaceuticals Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Nuvo Pharmaceuticals Chronic Idiopathic Urticaria Treatment Product
Table 124. Nuvo Pharmaceuticals Recent Developments/Updates
Table 125. Eli Lilly and Company Corporation Information
Table 126. Eli Lilly and Company Description and Business Overview
Table 127. Eli Lilly and Company Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Eli Lilly and Company Chronic Idiopathic Urticaria Treatment Product
Table 129. Eli Lilly and Company Recent Developments/Updates
Table 130. AstraZeneca plc Corporation Information
Table 131. AstraZeneca plc Description and Business Overview
Table 132. AstraZeneca plc Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. AstraZeneca plc Chronic Idiopathic Urticaria Treatment Product
Table 134. AstraZeneca plc Recent Developments/Updates
Table 135. AbbVie Inc. Corporation Information
Table 136. AbbVie Inc. Description and Business Overview
Table 137. AbbVie Inc. Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. AbbVie Inc. Chronic Idiopathic Urticaria Treatment Product
Table 139. AbbVie Inc. Recent Developments/Updates
Table 140. Celldex Therapeutics Corporation Information
Table 141. Celldex Therapeutics Description and Business Overview
Table 142. Celldex Therapeutics Chronic Idiopathic Urticaria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Celldex Therapeutics Chronic Idiopathic Urticaria Treatment Product
Table 144. Celldex Therapeutics Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Chronic Idiopathic Urticaria Treatment Distributors List
Table 148. Chronic Idiopathic Urticaria Treatment Customers List
Table 149. Chronic Idiopathic Urticaria Treatment Market Trends
Table 150. Chronic Idiopathic Urticaria Treatment Market Drivers
Table 151. Chronic Idiopathic Urticaria Treatment Market Challenges
Table 152. Chronic Idiopathic Urticaria Treatment Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Chronic Idiopathic Urticaria Treatment
Figure 2. Global Chronic Idiopathic Urticaria Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Chronic Idiopathic Urticaria Treatment Market Share by Type in 2023 & 2030
Figure 4. Tablets Product Picture
Figure 5. Capsules Product Picture
Figure 6. Creams Product Picture
Figure 7. Lotions Product Picture
Figure 8. Injections Product Picture
Figure 9. Global Chronic Idiopathic Urticaria Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Chronic Idiopathic Urticaria Treatment Market Share by Application in 2023 & 2030
Figure 11. Hospital Pharmacies
Figure 12. Online Pharmacies
Figure 13. Retail Pharmacies
Figure 14. Global Chronic Idiopathic Urticaria Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Chronic Idiopathic Urticaria Treatment Market Size (2019-2030) & (US$ Million)
Figure 16. Global Chronic Idiopathic Urticaria Treatment Sales (2019-2030) & (K Units)
Figure 17. Global Chronic Idiopathic Urticaria Treatment Average Price (US$/Unit) & (2019-2030)
Figure 18. Chronic Idiopathic Urticaria Treatment Report Years Considered
Figure 19. Chronic Idiopathic Urticaria Treatment Sales Share by Manufacturers in 2023
Figure 20. Global Chronic Idiopathic Urticaria Treatment Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest Chronic Idiopathic Urticaria Treatment Players: Market Share by Revenue in 2023
Figure 22. Chronic Idiopathic Urticaria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global Chronic Idiopathic Urticaria Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Chronic Idiopathic Urticaria Treatment Sales Market Share by Country (2019-2030)
Figure 25. North America Chronic Idiopathic Urticaria Treatment Revenue Market Share by Country (2019-2030)
Figure 26. United States Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Chronic Idiopathic Urticaria Treatment Sales Market Share by Country (2019-2030)
Figure 29. Europe Chronic Idiopathic Urticaria Treatment Revenue Market Share by Country (2019-2030)
Figure 30. Germany Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Netherlands Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Chronic Idiopathic Urticaria Treatment Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Chronic Idiopathic Urticaria Treatment Revenue Market Share by Region (2019-2030)
Figure 37. China Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. China Taiwan Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Australia Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Chronic Idiopathic Urticaria Treatment Sales Market Share by Country (2019-2030)
Figure 45. Latin America Chronic Idiopathic Urticaria Treatment Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Colombia Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Chronic Idiopathic Urticaria Treatment Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Chronic Idiopathic Urticaria Treatment Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Chronic Idiopathic Urticaria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Chronic Idiopathic Urticaria Treatment by Type (2019-2030)
Figure 56. Global Revenue Market Share of Chronic Idiopathic Urticaria Treatment by Type (2019-2030)
Figure 57. Global Chronic Idiopathic Urticaria Treatment Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Chronic Idiopathic Urticaria Treatment by Application (2019-2030)
Figure 59. Global Revenue Market Share of Chronic Idiopathic Urticaria Treatment by Application (2019-2030)
Figure 60. Global Chronic Idiopathic Urticaria Treatment Price (US$/Unit) by Application (2019-2030)
Figure 61. Chronic Idiopathic Urticaria Treatment Value Chain
Figure 62. Chronic Idiopathic Urticaria Treatment Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
